A hacker leaked millions of 23andMe users’ data, and the leak of ancestry data could have implications on health infonews2023-10-24T13:23:28+00:00October 24th, 2023|Endpoints News|
OrbiMed raises $4.3B to invest in biotech companies, as well as royalty deals and China startupsnews2023-10-24T12:30:55+00:00October 24th, 2023|Endpoints News|
Immutep reports PhII data of LAG-3 drug plus Keytruda in first-line NSCLCnews2023-10-24T11:21:36+00:00October 24th, 2023|Endpoints News|
Updated: Novartis ‘on track’ to complete restructuring post Sandoz spin, pushes back Pluvicto filingnews2023-10-24T11:15:35+00:00October 24th, 2023|Endpoints News|
Idorsia lays off up to 300 people, plans for pipeline prioritization in effort to extend cash runwaynews2023-10-24T11:06:42+00:00October 24th, 2023|Endpoints News|
Rampart Bioscience raises $125M for non-viral gene therapiesnews2023-10-24T11:00:54+00:00October 24th, 2023|Endpoints News|
Aiolos Bio launches with $245M Series A, chasing one of asthma’s hottest targetsnews2023-10-24T11:00:04+00:00October 24th, 2023|Endpoints News|
Heard at #ESMO23: Reflections on ADCs; Novartis and BeiGene falloutnews2023-10-24T10:30:32+00:00October 24th, 2023|Endpoints News|
Sanofi and Regeneron’s anti-inflammatory Dupixent rejected by FDA for chronic hives conditionnews2023-10-23T18:29:27+00:00October 23rd, 2023|Endpoints News|
FDA approves first subcutaneous version of blockbuster IBD drug infliximabnews2023-10-23T18:18:19+00:00October 23rd, 2023|Endpoints News|
